The role of ketoconazole in current prostate cancer care

Vaibhav Patel, Bobby Liaw, William Oh

Research output: Contribution to journalReview articlepeer-review

52 Scopus citations

Abstract

Ketoconazole is a nonselective steroid 17α-hydroxylase/17,20 lyase (CYP17A1) inhibitor that has been used, off-label, as a second-line therapy for castration-resistant prostate cancer (CRPC). The drug has shown clinical efficacy without survival benefit. Despite not improving survival, ketoconazole has beneficial characteristics, such as its low cost, a relatively favourable toxicity profile compared with chemotherapy, and its efficacy both before and after chemotherapy. The approval of several new, highly effective treatments, including abiraterone acetate, enzalutamide, and apalutamide, warrants re-evaluation of the role of ketoconazole and other classic agents in achieving the optimal timing and sequencing of available agents to prolong survival and maintain patients’ quality of life. In the current CRPC treatment landscape, we believe that ketoconazole can be considered in patients with nonmetastatic CRPC and in those with metastatic CRPC who do not respond to, tolerate, or have access to chemotherapy and other standard therapeutic options.

Original languageEnglish
Pages (from-to)643-651
Number of pages9
JournalNature Reviews Urology
Volume15
Issue number10
DOIs
StatePublished - 1 Oct 2018

Fingerprint

Dive into the research topics of 'The role of ketoconazole in current prostate cancer care'. Together they form a unique fingerprint.

Cite this